drugset / Trial / NCT00580684

Study Comparing Prevenar® to Pneumo 23 in Reducing Carriage in Children

NCT00580684 ↗

Phase 4 Completed 101 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelPrevention

Summary

To compare the ability of Prevnar® to Pneumo® 23 in reducing and preventing nasopharyngeal carriage of vaccine-type pneumococci one year after respective immunization. To evaluate the rate of penicillin-resistant pneumococci in nasopharyngeal carriage.

Timeline

Start
2003-09
Primary completion
—
Completion
2004-08

Drugs

EvaluationDrugModalityDoseRoute
Subject plain polisacaride vaccine 23 valent Vaccine — —
Comparator pneumococcus conjugate vaccine 7 valent Vaccine — —

Indications

No indication recorded.